Abstract

The aim of the study was to analyze the effects of early enteral nutrition suspension combined with nutritional support and somatostatin in serum inflammatory indices, gastrointestinal function, and outcomes in patients with severe acute pancreatitis. Among 84 severe acute pancreatitis individuals admitted in intensive care unit between June 2021 and June 2022, an observation group and a control group were divided with 42 patients in each group. The observation group was given with early enteral nutrition suspension and somatostatin within 24 h of intensive care unit admission, whereas early parenteral nutrition support and somatostatin was given to control group. Both the groups were compared with clinical efficacy, inflammatory markers, gastrointestinal function and complications. No significant difference (p>0.05) in serum levels of prealbumin, transferrin, procalcitonin, and amylase was observed before treatment between the two groups. Meanwhile the observation group showed significantly higher prealbumin and transferrin levels as well as lower procalcitonin and amylase levels after the treatment when compared with the control group (p<0.05). The observation group also exhibited high levels of interleukin-10, low levels of interleukin-6 and tumor necrosis factor-alpha, the latter difference was not statistically significant (p>0.05). Additionally, the observation group had lower modified Marshall, multiple organ failure scores, and Acute Physiology and Chronic Health Evaluation scores post-treatment, with a statistically significant difference (p<0.05). The incidence of complications in the observation group (16.67 %) was significantly lower than in the control group (40.48 %) (p<0.05). Early enteral nutrition suspension combined with somatostatin improves inflammatory markers, gastrointestinal function, and clinical outcomes in individuals with severe acute pancreatitis, and reduces the incidence of complications.